SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
 
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
MIDDLETON FRED A

(Last) (First) (Middle)
400 SOUTH EL CAMINO RD
SUITE 1200

(Street)
SAN MATEO CA 99402

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Stereotaxis, Inc. [ STXS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/17/2004
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/17/2004 C 41,335 A (2) 89,340 D
Common Stock 08/17/2004 C 10,023 A (2) 99,363 D
Common Stock 08/17/2004 C 2,215 A (2) 101,578 D
Common Stock 08/17/2004 C 1,403(1) A (2) 102,981 D
Common Stock 08/17/2004 C 248(1) A (2) 103,229 D
Common Stock 08/17/2004 C 433,709 A (2) 466,064 I Sanderling Venture Partners II, L.P.
Common Stock 08/17/2004 C 228,875 A (2) 694,939 I Sanderling Venture Partners II, L.P.
Common Stock 08/17/2004 C 52,925 A (2) 747,864 I Sanderling Venture Partners II, L.P.
Common Stock 08/17/2004 C 33,487(1) A (2) 781,351 I Sanderling Venture Partners II, L.P.
Common Stock 08/17/2004 C 167,750 A (2) 179,869 I Sanderling Management Limited, Cust. FBO Sanderling Ventures Limited, L.P.
Common Stock 08/17/2004 C 87,950 A (2) 267,819 I Sanderling Management Limited, Cust. FBO Sanderling Ventures Limited, L.P.
Common Stock 08/17/2004 C 19,441 A (2) 287,260 I Sanderling Management Limited, Cust. FBO Sanderling Ventures Limited, L.P.
Common Stock 08/17/2004 C 12,300(1) A (2) 299,560 I Sanderling Management Limited, Cust. FBO Sanderling Ventures Limited, L.P.
Common Stock 08/17/2004 C 2,185(1) A (2) 301,745 I Sanderling Management Limited, Cust. FBO Sanderling Ventures Limited, L.P.
Common Stock 08/17/2004 C 41,938 A (2) 44,967 I Sanderling Management Limited, Cust. FBO Middleton-McNeil, L.P.
Common Stock 08/17/2004 C 21,987 A (2) 66,954 I Sanderling Management Limited, Cust. FBO Middleton-McNeil, L.P.
Common Stock 08/17/2004 C 4,860 A (2) 71,814 I Sanderling Management Limited, Cust. FBO Middleton-McNeil, L.P.
Common Stock 08/17/2004 C 3,076(1) A (2) 74,890 I Sanderling Management Limited, Cust. FBO Middleton-McNeil, L.P.
Common Stock 08/17/2004 C 546(1) A (2) 75,436 I Sanderling Management Limited, Cust. FBO Middleton-McNeil, L.P.
Common Stock 08/17/2004 C 297,636 A (2) 297,636 I Sanderling IV Biomedical Co-Investment Fund, L.P.
Common Stock 08/17/2004 C 167,918(1) A (2) 465,554 I Sanderling IV Biomedical Co-Investment Fund, L.P.
Common Stock 08/17/2004 C 67,204(1) A (2) 532,758 I Sanderling IV Biomedical Co-Investment Fund, L.P.
Common Stock 08/17/2004 C 478 A (2) 478 I Sanderling V Beteiligungs GmbH & Co. KG
Common Stock 08/17/2004 C 33,758(1) A (2) 34,236 I Sanderling V Beteiligungs GmbH & Co. KG
Common Stock 08/17/2004 C 30,326(1) A (2) 64,562 I Sanderling V Beteiligungs GmbH & Co. KG
Common Stock 08/17/2004 C 25,272(1) A (2) 89,834 I Sanderling V Beteiligungs GmbH & Co. KG
Common Stock 08/17/2004 C 1,993 A (2) 1,993 I Sanderling V Biomedical Co-Investment Fund, L.P.
Common Stock 08/17/2004 C 140,660(1) A (2) 142,653 I Sanderling V Biomedical Co-Investment Fund, L.P.
Common Stock 08/17/2004 C 126,360(1) A (2) 269,013 I Sanderling V Biomedical Co-Investment Fund, L.P.
Common Stock 08/17/2004 C 105,300(1) A (2) 374,313 I Sanderling V Biomedical Co-Investment Fund, L.P.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Convertible Preferred Stock (2) 08/17/2004 C 148,806 (3) (3) Common Stock 41,335 (2) 0 D
Series B Convertible Preferred Stock (2) 08/17/2004 C 36,084 (3) (3) Common Stock 10,023 (2) 0 D
Series C Convertible Preferred Stock (2) 08/17/2004 C 7,976 (3) (3) Common Stock 2,215 (2) 0 D
Series D Convertible Preferred Stock (2) 08/17/2004 C 5,002 (3) (3) Common Stock 1,389 (2) 0 D
Series D-1 Convertible Preferred Stock (2) 08/17/2004 C 888 (3) (3) Common Stock 246 (2) 0 D
Series A Convertible Preferred Stock (2) 08/17/2004 C 1,561,354 (3) (3) Common Stock 433,709 (2) 0 I Sanderling Venture Partners II, L.P.
Series B Convertible Preferred Stock (2) 08/17/2004 C 823,950 (3) (3) Common Stock 228,875 (2) 0 I Sanderling Venture Partners II, L.P.
Series C Convertible Preferred Stock (2) 08/17/2004 C 190,530 (3) (3) Common Stock 52,925 (2) 0 I Sanderling Venture Partners II, L.P.
Series D Convertible Preferred Stock (2) 08/17/2004 C 119,472 (3) (3) Common Stock 33,186 (2) 0 I Sanderling Venture Partners II, L.P.
Series A Convertible Preferred Stock (2) 08/17/2004 C 603,903 (3) (3) Common Stock 167,750 (2) 0 I Sanderling Management Limited, Cust. FBO Sanderling Ventures Limited, L.P.
Series B Convertible Preferred Stock (2) 08/17/2004 C 316,622 (3) (3) Common Stock 87,950 (2) 0 I Sanderling Management Limited, Cust. FBO Sanderling Ventures Limited, L.P.
Series C Convertible Preferred Stock (2) 08/17/2004 C 69,988 (3) (3) Common Stock 19,441 (2) 0 I Sanderling Management Limited, Cust. FBO Sanderling Ventures Limited, L.P.
Series D Convertible Preferred Stock (2) 08/17/2004 C 43,885 (3) (3) Common Stock 12,190 (2) 0 I Sanderling Management Limited, Cust. FBO Sanderling Ventures Limited, L.P.
Series D-1 Convertible Preferred Stock (2) 08/17/2004 C 7,796 (3) (3) Common Stock 2,165 (2) 0 I Sanderling Management Limited, Cust. FBO Sanderling Ventures Limited, L.P.
Series A Convertible Preferred Stock (2) 08/17/2004 C 150,977 (3) (3) Common Stock 41,938 (2) 0 I Sanderling Management Limited, Cust. FBO Middleton-McNeil, L.P.
Series B Convertible Preferred Stock (2) 08/17/2004 C 21,987 (3) (3) Common Stock 21,987 (2) 0 I Sanderling Management Limited, Cust. FBO Middleton-McNeil, L.P.
Series C Convertible Preferred Stock (2) 08/17/2004 C 4,860 (3) (3) Common Stock 4,860 (2) 0 I Sanderling Management Limited, Cust. FBO Middleton-McNeil, L.P.
Series D Convertible Preferred Stock (2) 08/17/2004 C 3,047 (3) (3) Common Stock 3,047 (2) 0 I Sanderling Management Limited, Cust. FBO Middleton-McNeil, L.P.
Series D-1 Convertible Preferred Stock (2) 08/17/2004 C 541 (3) (3) Common Stock 541 (2) 0 I Sanderling Management Limited, Cust. FBO Middleton-McNeil, L.P.
Series C Convertible Preferred Stock (2) 08/17/2004 C 297,636 (3) (3) Common Stock 297,636 (2) 0 I Sanderling IV Biomedical Co-Investment Fund, L.P.
Series D Convertible Preferred Stock (2) 08/17/2004 C 166,410 (3) (3) Common Stock 166,410 (2) 0 I Sanderling IV Biomedical Co-Investment Fund, L.P.
Series E-2 Convertible Preferred Stock (2) 08/17/2004 C 47,402 (3) (3) Common Stock 47,402 (2) 0 I Sanderling IV Biomedical Co-Investment Fund, L.P.
Series C Convertible Preferred Stock (2) 08/17/2004 C 478 (3) (3) Common Stock 478 (2) 0 I Sanderling V Beteiligungs GmbH & Co. KG
Series D-1 Convertible Preferred Stock (2) 08/17/2004 C 33,455 (3) (3) Common Stock 33,455 (2) 0 I Sanderling V Beteiligungs GmbH & Co. KG
Series D-2 Convertible Preferred Stock (2) 08/17/2004 C 28,882 (3) (3) Common Stock 28,882 (2) 0 I Sanderling V Beteiligungs GmbH & Co. KG
Series E-2 Convertible Preferred Stock (2) 08/17/2004 C 17,825 (3) (3) Common Stock 17,825 (2) 0 I Sanderling V Beteiligungs GmbH & Co. KG
Series C Convertible Preferred Stock (2) 08/17/2004 C 1,993 (3) (3) Common Stock 1,993 (2) 0 I Sanderling V Biomedical Co-Investment Fund, L.P.
Series D-1 Convertible Preferred Stock (2) 08/17/2004 C 139,397 (3) (3) Common Stock 139,397 (2) 0 I Sanderling V Biomedical Co-Investment Fund, L.P.
Series D-2 Convertible Preferred Stock (2) 08/17/2004 C 120,343 (3) (3) Common Stock 120,343 (2) 0 I Sanderling V Biomedical Co-Investment Fund, L.P.
Series E-2 Convertible Preferred Stock (2) 08/17/2004 C 74,273 (3) (3) Common Stock 74,273 (2) 0 I Sanderling V Biomedical Co-Investment Fund, L.P.
Explanation of Responses:
1. The number of shares of common stock received upon conversion of the reporting person's convertible preferred stock includes additional shares issued as a result of antidilution provisions triggered by the issuer's initial public offering.
2. Price is not applicable to conversion of preferred stock to common stock.
3. All series of the Issuer's Convertible Preferred Stock are convertible into common stock upon demand at any time.
Remarks:
This is the first of two Form 4s filed by the reporting person on August 19, 2004.
/s/ Fred Middleton 08/18/2004
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Innovation Day